江苏金迪克生物技术股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported a significant increase in revenue for 2025, but also faced substantial losses due to increased R&D investments and asset impairment provisions [3][4]. Financial Data and Indicators - The company achieved an operating revenue of 113.23 million RMB, representing a year-on-year growth of 40.13% [3]. - The net profit attributable to the parent company was -173.47 million RMB, reflecting a year-on-year increase in losses of 85.53% [3]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was -180.00 million RMB, with a year-on-year increase in losses of 69.46% [3]. - Total assets as of December 31, 2025, were 1.42 billion RMB, a decrease of 7.24% from the beginning of the reporting period [3]. - Equity attributable to the parent company was 1.10 billion RMB, down 13.90% from the beginning of the reporting period [3]. Operational Performance and Financial Condition - The company improved production efficiency and accelerated the production and approval process for flu vaccines, contributing to revenue growth [3][6]. - Increased R&D investments for the quadrivalent flu vaccine project and the three-valent flu vaccine project negatively impacted profits [3][4]. - The company faced challenges with product quality and inventory management, leading to asset impairment provisions and inventory write-offs totaling approximately 41.99 million RMB [4][6].